Regentis Biomaterials Ltd. (RGNT)
NYSEAMERICAN: RGNT · Real-Time Price · USD
1.512
+0.022 (1.45%)
Oct 19, 2026, 12:36 PM EDT - Market open

Regentis Biomaterials Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-8.93-6.970.93-1.93-1.41-0.67
Net Income
-16.1-13.690.28-4.18-1.5-5.19
Earnings Per Share
-4.66-24.161.72-24.09-9.23-32.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8.957.380.230.351.242.74
Total Debt
0.031.24.957.626.476.08
Net Cash (Debt)
8.926.18-4.72-7.27-5.23-3.33
Net Cash Growth
44.36%-----
Net Cash Per Share
2.5810.91-29.08-41.90-32.26-20.54

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-3.84-1.38-0.64-1.22-1.50.13
Free Cash Flow
-3.84-1.38-0.64-1.22-1.50.13
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.